Abstract: The present invention relates to methods and pharmaceutical compositions for expressing a polynucleotide of interest in the retinal pigment epithelium of a subject. In particular, the present invention relates to a method for selectively expressing a polynucleotide of interest in the retinal pigment epithelium in an eye of a subject in need thereof comprising the step of transducing the retinal pigment epithelium with an amount of a rAAV2/5 vector containing the polynucleotide of interest.
Type:
Grant
Filed:
December 5, 2014
Date of Patent:
October 23, 2018
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
Inventors:
Christian Hamel, Vasiliki Kalatzis, Marie Pequignot, Nicolas Cereso
Abstract: A method for the expression of a protein of interest by a bacterium, notable in that it comprises the culturing of a bacterium temporarily or continuously expressing an Hsp protein, in that said bacterium also comprises a nucleic acid sequence, encoding a protein of interest, under the control of a lac promoter and in that said bacterium is cultured in a medium which does not contain IPTG or a metabolized molecule in such a way as to automatically induce the induction of transcription from the lac promoter.
Type:
Grant
Filed:
September 21, 2015
Date of Patent:
October 23, 2018
Assignees:
UNIVERSITE DE BOURGOGNE, INRA, INSERM
Inventors:
Fabrice Neiers, Renaud Seigneuric, Loïc Briand, Carmen Garrido-Fleury
Abstract: The present disclosure provides engineered polynucleotide sequences that form scaffolds and nucleoprotein complexes comprising such engineered polynucleotide sequences that form scaffolds and nucleic acid binding proteins. Nucleic acid sequences encoding the engineered polynucleotide sequences that form scaffolds, as well as expression cassettes, vectors and cells comprising such polynucleotide sequences, are described. A variety of methods for making and using the engineered polynucleotide sequences that form scaffolds are also disclosed.
Abstract: The present disclosure provides viral microparticles comprising genetically-engineered baculoviruses (at least partially) embedded in a polymeric matrix for the local delivery of therapeutic nucleic acid molecules to the cells of a vertebrate individual (optionally in combination with a medical implant such as vascular stent platform). The viral microparticles are especially useful for promoting the healing of a wound as well as the repair of a blood vessel and prevent pathological scarring. Also provided herein are processes for making the viral microparticles, pharmaceutical compositions comprising viral microparticles as well as supports comprising the viral microparticles for the locating the viral microparticles in a wound or in the vicinity of a wound.
Abstract: A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.
Abstract: Described herein is an engineered Kluyveromyces marxianus cell, the cell comprising in its genome: (i) two different nucleic acid molecules that each contain a promoter operably linked to a gene encoding a functional enzyme, and (ii) a selection nucleic acid molecule that contains a promoter operably linked to a gene encoding a selectable marker, wherein all of the nucleic acids molecules of (i) and (ii) are in tandem and the engineered cell expresses all of the proteins encoded by the genes of (i) and (ii).
Abstract: Provided herein are methods of detecting nucleic acids. The nucleic acid of interest may be detected by using Cas endonuclease to degrade substantially all nucleic acid in a sample except for the nucleic acid of interest, leaving the nucleic acid of interest isolated and amenable to detection. In related methods, Cas endonuclease complexes are used to protect the nucleic acid of interest while unprotected nucleic acid is digested, e.g., by exonuclease, after which the isolated nucleic acid of interest is detected.
Type:
Grant
Filed:
January 23, 2018
Date of Patent:
September 25, 2018
Assignee:
GENETICS RESEARCH, LLC
Inventors:
Anthony P. Shuber, William Glover, Thomas C. Meyers
Abstract: The present invention relates to the field of fungal biotechnology, more particularly to a strong inducible gene expression system in fungal species, such as a species of the Rhodosporidium genus or the Rhodotorula genus.
Type:
Grant
Filed:
March 31, 2016
Date of Patent:
September 25, 2018
Assignee:
TEMASEK LIFE SCIENCES LABORATORY LTD
Inventors:
Lianghui Ji, Yanbin Liu, Chong Mei John Koh
Abstract: The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell through at least five cell divisions, and methods of introducing such single-celled organisms into eukaryotic cells. The invention also provides methods of using such eukaryotic cells. The invention further provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetotactic bacteria.
Abstract: Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
Abstract: The invention pertains to compositions and methods for identifying gRNAs that are effective in treating a latent HIV infection. An embodiment of the invention provides a cell having incorporated into its genome: a gene that expresses a CRISPR-Cas protein and an HIV pseudovirus genome, wherein the HIV pseudovirus genome has a first marker gene encoding a first marker protein under the control of HIV-1 LTR promoter and a second marker gene inserted into the nef gene of the HIV pseudovirus and encoding a second marker protein under the control of a constitutive promoter. Screening methods for identifying gRNAs that can treat a latent HIV infection are also provided. Further, compositions comprising a CRISPR-Cas protein and gRNAs that can treat a latent HIV infection are provided. Furthermore, a method for treating a latent HIV infection in a subject by administering the compositions of CRISPR-Cas protein and gRNAs are described.
Type:
Grant
Filed:
March 3, 2017
Date of Patent:
September 4, 2018
Assignee:
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
Abstract: The invention relates to yeast cells modified to express a functional type I RuBisCO enzyme, and a class II phosphoribulokinase. The expression of these enzymes recreates a Calvin cycle in said yeasts in order to enable the yeasts to use carbon dioxide.
Type:
Grant
Filed:
January 16, 2015
Date of Patent:
September 4, 2018
Assignees:
Institut National de la Recherche Agronomique, Institut National Des Sciences Appliquees De Toulouse, Centre National de la Recherche Scientifique
Abstract: Provided are modified microorganisms which are modified such that their growth can be controlled using exogenously provided compounds. The microorganisms can be modified by genetic alterations that include a promoter inducible by a first exogenously supplied compound. The promoter can be configured to drive expression of an RNA coding sequence that may be essential to growth of the microorganism. The microorganisms may also be modified to include site specific recombinase recognition sites flanking or within the RNA coding sequence so that expression of the corresponding site specific recombinase will disrupt transcription of the RNA. The site specific recombinase can be configured such that it expression and/or activity is suppressed by a second exogenously supplied compound. Methods of making the modified microorganisms and kits that contain reagents for making and using the modified microorganisms are also provided.
Type:
Grant
Filed:
January 19, 2016
Date of Patent:
August 28, 2018
Assignees:
New York University, The Johns Hopkins University
Abstract: The present disclosure provides a HTP microbial genomic engineering platform that is computationally driven and integrates molecular biology, automation, and advanced machine learning protocols. This integrative platform utilizes a suite of HTP molecular tool sets to create HTP genetic design libraries, which are derived from, inter alia, scientific insight and iterative pattern recognition. The HTP genomic engineering platform described herein is microbial strain host agnostic and therefore can be implemented across taxa. Furthermore, the disclosed platform can be implemented to modulate or improve any microbial host parameter of interest.
Type:
Grant
Filed:
March 16, 2018
Date of Patent:
August 14, 2018
Assignee:
Zymergen Inc.
Inventors:
Zach Serber, Erik Jedediah Dean, Shawn Manchester, Katherine Gora, Michael Flashman, Erin Shellman, Aaron Kimball, Shawn Szyjka, Barbara Frewen, Thomas Treynor, Kenneth S. Bruno
Abstract: Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
Abstract: The present invention relates to the field of chromosome engineering. More specifically, the present invention provides methods and compositions useful for inducibly linearizing circular DNA molecules in vivo in yeast. In one embodiment, a comprises a nucleic acid encoding a selectable marker, wherein the nucleic acid encoding a selectable marker comprises an intron comprising an endonuclease recognition site flanked by telomere seed sequences.
Abstract: A method for using cloning vector plasmids to produce DNA molecules, such as transgenes, in a single cloning step. The transgenes can be used for the purpose of gene expression or analysis of gene expression. The plasmid cloning vectors are engineered to minimize the amount of manipulation of DNA fragment components by the end user of the vectors and the methods for their use. Transgenes produced using the invention may be used in a single organism, or in a variety of organisms including bacteria, yeast, mice, and other eukaryotes with little or no further modification.
Abstract: The invention relates to anti-sigma factors (“anti-sigmas”) that bind to sigma factors and block activation of transcription. Anti-sigmas and their cognate sigma factors provide a highly effective mechanism for regulating gene expression in genetic circuits.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
July 24, 2018
Assignees:
Massachusetts Institute of Technology, The Regents of the University of California
Inventors:
Virgil A. Rhodius, Christopher Voigt, Carol A. Gross
Abstract: The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.
Abstract: Embodiments herein include polynucleotides, vectors and methods for the insertion and expression of transgenes. In an embodiment, a polynucleotide is included. The polynucleotide can include a JeT promoter or variant thereof, an intron sequence less than 400 bases in length, and a polynucleotide sequence encoding a polypeptide or protein operatively linked to the promoter. In an embodiment, a recombinant vector is included. The recombinant vector can include a JeT promoter or variant thereof, an intron sequence less than 400 bases in length, and a polynucleotide sequence encoding a polypeptide or protein operatively linked to the promoter. Other embodiments are also included herein.